A Study Found a Link Between Shingles and Chronic Fatigue Syndrome (CFS); polyDNA Recommends Gene-Eden-VIR and Novirin to Reduce Fatigue Linked to a Viral Infection

“The HZ (herpes zoster/shingles) cohort showed a significantly higher cumulative incidence rate of developing CFS (chronic fatigue syndrome),” according to a study published on May 1, 2014 in The European Journal of Clinical Microbiology & Infectious Diseases (1). polyDNA reviews the study and recommends that patients with severe fatigue talk to their doctors about Gene-Eden-VIR and Novirin.

Rochester, NY (PRWEB) May 21, 2014 -- Many studies found a link between Chronic Fatigue Syndrome (CFS) and the Epstein Barr Virus (EBV). Now, a new study found a link between the varicella zoster virus (VZV), the virus that causes Chickenpox and Shingles, and CFS. “This study evaluated the association between herpes zoster (HZ) infection and the risk of CFS, and examined the possibility of patients developing postviral fatigue effects, including the possibility of developing other unexplainable chronic fatigue conditions (1).” The study found that “the HZ cohort showed a significantly higher cumulative incidence rate of developing CFS than the non-HZ patients (1).” polyDNA recommends that individuals who have had Chickenpox or Shingles talk to their doctors about Gene-Eden-VIR and Novirin. The antiviral formula of these natural products was shown to reduce viral symptoms, including fatigue, in two post-marketing clinical studies that followed FDA guidelines.

Another study suggested that “Virtually all CFS symptoms could be produced by an infection of the peripheral ganglia (a group of nerve cell bodies located in the peripheral nervous system), with infection of the autonomic ganglia (a cluster of nerve cell bodies (a ganglion) in the autonomic nervous system), causing fatigue, postural hypotension, and sleep disturbances, and infection of the sensory ganglia causing sensory symptoms such as chronic pain. Furthermore, infections of the peripheral ganglia are known to cause long-term nerve dysfunction, which would help explain the chronic course of CFS.” (See The Middle East Molecular Biology Congress & Exhibition, from 2009) (2). In addition, “VZV is known to frequently reactivate in the peripheral ganglia of previously healthy adults and cause sudden, debilitating illness, making it a likely candidate as a cause of CFS. Moreover, many of the symptoms of CFS overlap with those of herpes zoster (Shingles), with the exception that painful rash is not one of the symptoms of CFS (2).”

To make things worse, “Co-infection with multiple herpesviruses is a possibility, as some CFS patients show signs of infection with other herpesviruses including Epstein-Barr, Cytomegalovirus, and HHV6. These three herpesviruses can attack immune cells, and may therefore promote neurotropic herpesvirus reactivation in the ganglia (2).” In other words, an infection with one or more of these herpesviruses, including VZV, may contribute to the development of CFS.

Chronic Fatigue Syndrome is a “devastating disease that still puzzles doctors, and only a fraction of sufferers are properly diagnosed. Once derided as ‘yuppie flu,’ CFS actually cuts across all races and economic groups. But it still battles a heavy stigma, and research funding is scarce. Thirty years after its first discovery, there is no single diagnostic test and no treatment.” (See AlJazeera.com, from January 3, 2014) (3).

CFS usually occurs during the latent phase of a viral infection, which follows an active infection. “Almost all patients reported a previous infection as the onset of fatigue symptom.” (See the International Journal of
Pediatrics, from 2013) (4). Moreover, “Almost all patients reported themselves to be previously healthy prior to their fatigue and also ascribed the onset due to an infection (4)”.

“We recommend that patients with severe fatigue talk to their doctors about Gene-Eden-VIR and Novirin. The formula of these natural antivirals was shown to reduce fatigue in patients with a viral infection.” – Mike Evans, polyDNA

As far as we know, the only two products currently available that target latent viruses such as VZV (and other latent herpesviruses) are Gene-Eden-VIR, and Novirin.

Novirin shares the same formula as Gene-Eden-VIR. The difference between the two is that Novirin has higher quality, more expensive ingredients. The Novirin/Gene-Eden-VIR formula was tested in two post-marketing clinical studies published in September 2013 and March 2014, respectively, in the peer reviewed medical journal Pharmacy & Pharmacology (5).


Up to 70% of those studied reported a decrease in symptoms associated with CMV infection, and users of the Novirin/Gene-Eden-VIR formula experienced an increase in overall health (5).

Each ingredient of Novirin was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the highest quality, safest, most effective natural ingredients that target latent viruses.

A second clinical study showed that the Novirin/Gene-Eden-VIR formula decreased physical and mental fatigue. (See Pharmacology & Pharmacy, from March, 2014) (6).


All orders of these products are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

References:


polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Novirin, an antiviral natural remedy that helps the immune system kill latent viruses.
Contact Information
Mike Davis
PolyDNA
http://gene-eden-kill-virus.com/
+1 5852509999

Online Web 2.0 Version
You can read the online version of this press release here.